Multidrug Resistance in Newly Diagnosed TB Patient

Launched by ASSIUT UNIVERSITY · Nov 15, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how to better diagnose and treat patients who have newly diagnosed tuberculosis (TB), especially those with a type called multidrug-resistant TB (MDR-TB). MDR-TB is a serious form of TB that does not respond to the standard treatments. The trial will use a tool called GeneXpert, which helps doctors quickly identify TB in patients, to see how effective it is in catching these resistant cases early. This is important because early detection can lead to better treatment outcomes.

To be part of this trial, participants need to be newly diagnosed with TB, confirmed through a test that checks for the bacteria in their sputum or other body fluids. Unfortunately, those who have been treated for TB before will not be eligible. While the trial is not yet recruiting participants, once it starts, those who take part can expect to contribute to important research that aims to improve TB diagnosis and treatment, potentially helping many others in the future.

Gender

ALL

Eligibility criteria

• • Inclusion criteria
• • newly diagnosed tuberculosis patient
• • Diagnosed by direct smear for sputum or body fluid
• Exclusion Criteria:
• • \* previously treated patient